Product Review – Gla-300 in patients with type 2 diabetes mellitus: Sustained glycaemic control with lower risk of hypoglycaemia and observed lower weight gain

As part of our series focussing on medicines available in Australia, we have added a product review which explores clinical and real-world evidence supporting the use of insulin glargine 300 U/mL (Gla-300) in people with type 2 diabetes. Drawing on data from the EDITION clinical trial programme, post-hoc analyses, and real-world studies such as DELIVER-G, the review provides a summary of Gla-300’s impact on hypoglycaemia, glycaemic control, and weight gain.

Guiding commenatry has been provided by Dr Ted Wu, a senior specialist endocrinologist and the Director of the Diabetes Centre at The Royal Prince Alfred Hospital in Sydney, Australia, and an Honorary Professor at the Shijiazhuang Diabetes Hospital in Hebei, China.